PCOD vs PCOS: One Condition, Two Names

No. They are two names for one condition. PCOS — polycystic ovary syndrome — is the term used in clinical guidelines and research worldwide. PCOD, polycystic ovarian disease, is an older name that is still in everyday use in India, including by doctors, but it is not a separate diagnosis and it does not describe a milder version of anything.

The plainest evidence for that is what the guidelines contain. The 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, published in parallel in Human Reproduction, the Journal of Clinical Endocrinology and Metabolism and the European Journal of Endocrinology, runs to 254 recommendations and practice points. Searched end to end, it uses the term PCOD zero times, and the phrase polycystic ovarian disease zero times.

• PCOD is not an early stage of PCOS.
• PCOD is not a milder grade, and no grading system exists.
• No guideline body publishes separate criteria for PCOD.
• No prevalence, risk or treatment figure exists for PCOD alone, because it is not a category anyone counts.

If you were recently handed one of these labels and a diet sheet, one thing is worth saying early: a great many women hear this diagnosis as "I will not be able to have children". That is not what it means. PCOS is the most common cause of anovulation worldwide, according to the World Health Organization, and anovulation is among the more treatable reasons for not conceiving.

This is the distinction most sites invent, and it is worth naming so it can be dismissed. The claim runs: PCOD is a disease or disorder of the ovaries, so it is localised and mild; PCOS is a syndrome, so it is systemic and serious. Neither half of that holds.

A syndrome simply means a recognised cluster of features rather than a single defining abnormality. The Rotterdam 2003 consensus, which is where the current criteria come from, put it directly: PCOS remains a syndrome and, as such, no single diagnostic criterion is sufficient for clinical diagnosis. That is a statement about how the diagnosis is made, not about how severe it is.

And the word "disorder" carries no lesser weight. The World Health Organization's own fact sheet on the condition calls PCOS "a common hormonal disorder" in its first line, and in the same document describes it as a chronic metabolic condition that persists beyond the reproductive years. The two words are used interchangeably by the bodies that write the guidance. Severity in PCOS varies enormously between individuals, but it varies within one diagnosis — driven by which features you have and how marked they are, not by which of two names your report happened to use.

Two of three Rotterdam features, with other causes excluded. That is the whole of it, and knowing which two you meet is more useful than knowing which label you were given.

1. Irregular cycles or ovulatory dysfunction. For an adult the 2023 guideline defines irregular as shorter than 21 days, longer than 35 days, or fewer than 8 cycles a year (rec 1.1.1). Where cycles are regular but ovulation is in doubt, a serum progesterone level can check it (rec 1.1.5).
2. Androgen excess, clinically or biochemically. The guideline asks for total and free testosterone, and for laboratories to use mass spectrometry rather than direct immunoassays, which it says have limited accuracy here (recs 1.2.1, 1.2.4).
3. Polycystic ovarian morphology on ultrasound — or, in adults only, a raised AMH instead of the scan (rec 1.5.1).

Where the first two are present, the third adds nothing. The guideline states that in patients with irregular menstrual cycles and hyperandrogenism, an ovarian ultrasound is not necessary. WHO says the same more plainly: ovarian cysts are not required for a PCOS diagnosis. The follicles on such a scan are not cysts in the usual sense — they are ordinary immature follicles, present in larger numbers, which is why the name is widely considered a poor one.

AMH's role is real but bounded. Rec 1.5.5 says either AMH or ultrasound may be used, but not both, to limit overdiagnosis. Rec 1.5.3 is the one most often lost: serum AMH should not be used as a single test for the diagnosis of PCOS. Rec 1.5.4 says it should not yet be used in adolescents at all. More on what an AMH result does and does not tell you.

No, and that is the practical reason the naming matters so little. Management follows from which features you have and what you want, in a fixed order.

• A healthy lifestyle is recommended for everyone with the diagnosis, for metabolic health including central adiposity and lipid profile (rec 3.1.1) — with benefits even in the absence of weight loss (rec 3.1.5).
• If you are trying to conceive and the obstacle is ovulation, rec 5.3.1 states letrozole should be the first-line pharmacological treatment for ovulation induction in infertile anovulatory women with PCOS with no other infertility factors. Rec 5.4.5.1 puts it ahead of clomiphene citrate.
• Gonadotrophins are second-line, after first-line oral ovulation induction has failed (rec 5.5.5). IVF sits third.
• Metformin is not the ovulation drug. Rec 4.3.1 places it in adults with a BMI of 25 or above for metabolic and anthropometric outcomes.

One thing worth knowing before you are told otherwise: ovulation induction agents, letrozole among them, are off-label in many countries (rec 5.3.2). Being prescribed letrozole is not a sign something unusual is happening. And if you are already on metformin, do not stop it because someone told you your label is the milder one — there is no milder label. Our fuller article on PCOS and fertility walks the treatment ladder, and whether PCOD can be cured naturally takes the management-versus-cure question.

Several things are routinely asserted about these two terms that no retrievable source supports.

• That PCOD and PCOS are separate entities with separate criteria. No guideline body defines PCOD, so there is nothing to compare.
• That either name carries a severity grade. Neither the Rotterdam consensus nor the 2023 guideline grades PCOS by severity at all.
• That a single blood test settles it. Rec 1.5.3 rules AMH out as a standalone diagnostic, and rec 3.1.10 says the insulin assays available in routine practice are of limited clinical relevance and should not be used in routine care.
• That an Indian guideline exists that treats PCOD separately. We could not retrieve any Indian national guidance on PCOS while preparing this page, so nothing here is attributed to one.

The quality of the underlying evidence deserves stating too. The 2023 guideline authors describe the evidence base in PCOS as improved but still generally low to moderate quality, which is why many of their 254 items are practice points rather than evidence-based recommendations.